Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
Insmed Inc.’s Chief Medical Officer, Martina Flammer, M.D., reported a planned stock sale. On 02/05/2026 she sold 869 shares of Insmed common stock at $152.44 per share in a transaction coded as a sale. After this trade, she beneficially owned 83,243 shares directly.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that she adopted on February 27, 2025. Such plans allow insiders to schedule trades in advance, helping separate routine portfolio moves from day-to-day corporate developments.
A holder of common stock in a NASDAQ‑listed company has filed a Form 144 notice to sell 869 shares through Merrill Lynch, with an aggregate market value of $132,462. The filing states that 213,273,469 shares of this class were outstanding and lists an approximate sale date of February 5, 2026.
The securities to be sold were acquired on February 1, 2026 via stock plan activity from the issuer. The person filing, identified in recent sales as Martina Flammer, also sold multiple blocks of common shares between November 11, 2025 and February 3, 2026, with individual trades ranging from hundreds to tens of thousands of shares.
INSMED Inc.'s Chief Operating Officer Roger Adsett reported a routine sale of company stock in connection with equity compensation. On February 3, 2026, he sold 791 shares of common stock at a price of $156.17 per share. A footnote explains that the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees, rather than as a discretionary open-market sale. After this transaction, Adsett beneficially owned 106,810 shares of INSMED common stock directly.
Insmed Inc.'s Chief Financial Officer, Sara Bonstein, reported a small share sale under a Form 4 filing. On 02/03/2026, she sold 748 shares of Insmed common stock at a price of
Insmed Inc. Chair and CEO William Lewis reported a routine share sale linked to tax withholding. On February 3, 2026, he sold 3,009 shares of common stock at $156.34 per share to satisfy tax obligations from vested restricted stock units and related broker fees. After this sale, he directly owned 303,882 shares of Insmed common stock. In addition, he had indirect beneficial ownership of 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust.
INSMED Inc's Chief Legal Officer reports a routine share sale related to equity compensation. On 02/03/2026, Michael Alexander Smith sold 640 shares of INSMED common stock at $156.27 per share. The filing explains the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. After this transaction, he directly beneficially owned 56,397 shares of common stock.
Insmed Inc.’s Chief Medical Officer Martina Flammer reported a series of stock transactions. On February 2, 2026, she exercised a stock option for 7,982 shares of common stock at
Insmed common stockholder files notice to sell shares under Rule 144. The filing covers a planned sale of 791 common shares of Insmed through Merrill Lynch on the NASDAQ, with an aggregate market value of 123,526 and 213,273,469 shares outstanding.
The shares to be sold were acquired on 02/01/2026 via stock plan activity from the issuer. The notice also lists recent sales by Roger Adsett during January 2026, including 2,059 common shares for gross proceeds of 358,616, 802 shares for 140,406, and 1,429 shares for 247,688.
A shareholder of INSM has filed a notice under Rule 144 to sell 640 shares of common stock through Merrill Lynch on the NASDAQ, with an approximate sale date of 02/03/2026. The shares were acquired on 02/01/2026 via stock plan activity from the issuer.
The notice also lists earlier sales by Michael Smith over the past three months, including 27,130 common shares sold on 11/03/2025 for gross proceeds of 4,985,054, alongside several smaller sales in January 2026.
William Lewis filed a notice of proposed sale under Rule 144 to sell 3,009 shares of common stock through Merrill Lynch in Washington, DC. The shares are listed on NASDAQ, and the approximate sale date stated is February 3, 2026.
The shares to be sold were acquired on February 1, 2026 via stock plan activity from the issuer. Over the prior three months, William Lewis reported several other common stock sales, including blocks of 19,215 and 10,699 shares, with disclosed gross proceeds for each transaction.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
